We are live on ! Find out more

Vir Biotechnology

VIR

Market cap $1.83B

10.81 USD

-0.37

3.31%

At close Updated Sep 9, 4:00 PM EDT

Pre-market

After hours

10.81

0.00

0%

1 day

-3.31%

5 days

-7.05%

1 month

21.6%

3 months

27.03%

6 months

10.31%

Year to date

81.99%

1 year

106.3%

5 years

-78.17%

10 years

-22.9%

About: Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Employees: 367

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 77.8%

Negative 11.1%

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, In.

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500.

Vir Biotechnology Q2 Earnings Call Highlights

Zacks Investment Research

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to a loss of $0.8 per share a year ago.

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. “This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology Announces Chief Financial Officer Transition

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O'Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep in.

Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powe.

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for prostate cancer. Updated data from VIR-5818 are due in H2'26 and could include a further ~18 months of data.

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has he.

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phas.

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

See News Rankings

Price charts implemented using Lightweight Charts™